Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 25;10:2045125320926347. doi: 10.1177/2045125320926347

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2020

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — Achievement of SR during the treatment period in the whole population over time (A) and in subgroups at LOCF endpoint: PANSS remission symptom severity criterion at baseline – yes versus no; >6 months prior PP1M versus 4–6 months prior PP1M; and switched from PP1M polytherapy versus PP1M monotherapy (B), and in patients who met and did not meet the PANSS severity criterion for remission at baseline (C) (mITT population).

LOCF, last observation carried forward; mITT, modified intent-to-treat; PANSS, positive and negative syndrome scale; PP1M, paliperidone palmitate 1-month formulation; SR, symptomatic remission.